{"product_id":"soranni-sorafenib-200mg-2","title":"Soranni (Sorafenib)","description":"\u003cstrong\u003eIndications\u003c\/strong\u003e\r\n\r\nIncluding: unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and local recovery that is refractory to radioactive iodine therapy\r\n\r\nHair or metastasis, and advanced differentiated thyroid cancer.\r\n\r\n\u003cstrong\u003eDose and administration method\u003c\/strong\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eMethod of administration\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e400mg (2 tablets) orally, twice a day, on an empty stomach.\u003c\/li\u003e\r\n \t\u003cli\u003eTo deal with suspected adverse drug reactions, treatment may need to be interrupted and\/or dose reduced. The dose can be reduced To 400mg once a day or to 400mg, once every other day.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"2\"\u003e\r\n \t\u003cli\u003eDosage specifications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTablets, 200mg.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"3\"\u003e\r\n \t\u003cli\u003eContraindications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePeople who are known to be allergic to sorafenib or any other components of the drug should not use sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eIn patients with squamous cell lung cancer, sorafenib is contraindicated in combination with carboplatin and paclitaxel.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eWarnings and Precautions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMyocardial ischemia and\/or infarction: consider temporarily or permanently discontinuing sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eBleeding: If bleeding requires medical intervention, consider discontinuing sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eHypertension: 6 weeks before treatment, regularly monitor blood pressure every week. Follow-up treatment should also be monitored regularly.\u003c\/li\u003e\r\n \t\u003cli\u003eSkin toxicity: Interrupt and\/or reduce the dose. Severe or persistent skin toxicity, or pregnant Stop taking the medication when you suspect Stevens-John syndrome and toxic epidermal necrolysis.\u003c\/li\u003e\r\n \t\u003cli\u003eGastrointestinal perforation: stop taking sorafenib.\u003c\/li\u003e\r\n \t\u003cli\u003eProlonged QT interval: Patients with high risk of ventricular arrhythmia regularly monitor ECG and electrolyte levels.\u003c\/li\u003e\r\n \t\u003cli\u003eDrug-induced hepatotoxicity: monitor liver function regularly; stop if there is an unexplained rise in transaminase Stop taking medicine.\u003c\/li\u003e\r\n \t\u003cli\u003eEmbryo toxicity: It is recommended that women of childbearing age avoid pregnancy when taking the drug.\u003c\/li\u003e\r\n \t\u003cli\u003eThyroid-stimulating hormone (TSH) damage in differentiated thyroid cancer (DTC): monitor TSH once a month,\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n(Please read this notice carefully and take the medicine according to this notice or under the guidance of a doctor)\r\n\u003cul\u003e\r\n \t\u003cli\u003eThyroid replacement therapy is suitable for patients with thyroid cancer.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAdverse reactions\u003c\/strong\u003e\r\n\r\nThe most common adverse reactions related to sorafenib (≥20%): diarrhea, fatigue, infection, baldness, Hand and foot skin reactions, rash, weight loss, anorexia, nausea, gastrointestinal pain and abdominal pain, high blood pressure and blood.\r\n\r\n\u003cstrong\u003estorage method\u003c\/strong\u003e\r\n\r\nShading, cool and dry place","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948493867,"sku":"RL1420230901102","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655894917-557e1a1ef535bfa.png?v=1787022116","url":"https:\/\/xomeds.com\/products\/soranni-sorafenib-200mg-2","provider":"XOMEDS","version":"1.0","type":"link"}